Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

38 Results

Drug Safety & Advice

Reference List for Appendix 2 - Extravasation Potential of Various Chemotherapy/Supportive Agents

Jul 2015

Statistical Reports

Cancer in the Métis People of Ontario: Risk Factors and Screening Behaviours

Jul 2015

Statistical Reports

Cancer Risk Factors in Ontario: Healthy Weights, Healthy Eating and Active Living

Mar 2015

Guidelines and Advice

Cancer Care Ontario’s Focus on Take-Home Cancer Drugs and Community Practice

Status: Current
ID: GL-C50-17

Jan 2015

Guidelines and Advice

Clinical Verification of Cancer Drug Prescriptions Checklist: Cancer Centres and Specialty Pharmacies

Status: Current
ID: GL-C50-18

Jan 2015

Guidelines and Advice

Recommended Criteria of a Pre-printed Order (PPO): Oral Chemotherapy Take-home Prescriptions

Status: Current
ID: GL-C50-21

Jul 2015

Guidelines and Advice

Person-Centred Care Guideline

Status: Current
ID: GL-C50-20

May 2015

Drug

medroxyprogesterone

Other Name(s): Provera® (multiple brands available)

Quick Link(s): Drug Monograph, Patient Info Sheet

Apr 2015

Guidelines and Advice

Focal Tumour Ablation in Ontario: Recommendations Report 2015

Status: Current
ID: GL-C50-19

Jan 2015

Guidelines and Advice

Guidance for Kyphoplasty and Vertebroplasty for Cancer Patients in Ontario: Recommendations Report 2017

Status: Current
Version: 2

Oct 2018

Guidelines and Advice

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2018

Status: Current
ID: pet 2018-1
Version: n/a

Oct 2018

Guidelines and Advice

Cancer Screening for Persons at Risk for or Affected with Lynch Syndrome Evidence Summary

Status: In-Review
ID: ES 15-16

Oct 2018

Pages